Extended stability program testing of two adenoviral HIV vaccine candidates
Ended Purchase Order Awarded Last action
- Contract number
- 75N93022P01224
- Awardee
-
Emergent Travel Health Inc. UEI CXEUFMM1FXY8 Part of Emergent Biosolutions Inc.
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $697,945
Award facts
- Opportunity
-
- Stability Testing for HIV Adenoviral Vaccine Candidates Pre-Solicitation · NOINIAID222130529 · Posted Aug 2, 2022
- Contract value 75% obligated
-
- $697,944.78 Current, with exercised options
- $936,198.80 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Montgomery Village, MD 20879, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $235,429 | |
| Exercise an Option | $232,637 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $229,879 |
About this award
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, awarded a sole-source, firm-fixed-price purchase order to Emergent Travel Health Inc. for extended stability program testing of two adenoviral human immunodeficiency virus (HIV) vaccine candidates currently in clinical trials. The contract has a 1-year base period starting August 26, 2022, with four 1-year option periods, for a total potential period of performance through August 25, 2027 and a ceiling value of $936,198.80. Emergent Travel Health Inc. developed and manufactured the vaccine candidates and has the proprietary assays required for the stability testing. This contract does not have a set-aside designation.
Quick answers
Who was awarded contract 75N93022P01224?
75N93022P01224 was awarded to Emergent Travel Health Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 16, 2022.
How much is contract 75N93022P01224 worth?
The government has obligated $697,945 on 75N93022P01224. Its potential value, with all options, is $936,199.
Was contract 75N93022P01224 competed?
The extent of competition for 75N93022P01224 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award